Diagnostic Value of Vaginal Discharge, Wet Mount and Vaginal
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Discovery of Different Types of Cervical Mucus and the Billings Ovulation Method
The Discovery of Different Types of Cervical Mucus and the Billings Ovulation Method Erik Odeblad Emeritus Professor, Dept. of Medical Biophysics, University of Umeå, Sweden Published with permission from the Bulletin of the Ovulation Method Research and Reference Centre of Australia, 27 Alexandra Parade, North Fitzroy, Victoria 3068, Australia, Volume 21, Number 3, pages 3-35, September 1994. Copyright © Ovulation Method Research and Reference Centre of Australia 1. Abstract 2. Introduction 3. Anatomy and Physiology 4. What is Mucus? 5. The Commencement of my Research 6. The Existence of Different Types of Crypts and of Mucus 7. Identification and Description of G, L, and S Mucus 8. G- and G+ Mucus 9. Age, Pregnancy, the Pill and Microsurgery 10. P Mucus 11. F Mucus 12. The Role of the Vagina 13. The Different Types of Secretions and the Billings Ovulation Method 14. Early Infertile Days 15. The Days of Possible Fertility 16. Late Infertile Days 17. Anovulatory Cycles 18. Lactation 19. Diseases and the Billings Ovulation Method 20. The Future 21. Acknowledgements 22. Author's Note 23. References 24. Appendix Abstract An introduction to and some new anatomical and physiological aspects of the cervix and vagina are presented and also an explanation of the biosynthesis and molecular structure of mucus. The history of my discoveries of the different types of cervical mucus is given. In considering my microbiological investigations I suspected the existence of different types of crypts and cervical mucus and in 1959 1 proved the existence of these different types. The method of examining viscosity by nuclear magnetic resonance was applied to microsamples of mucus extracted 1 outside of several crypts. -
Statistical Analysis Plan: IT001-302
Statistical Analysis Plan: IT001-302 Study Title: A prospective, Phase 3, randomized, multi-center, double-blind, double dummy study of the efficacy, tolerability and safety of intravenous sulopenem followed by oral sulopenem-etzadroxil with probenecid versus intravenous ertapenem followed by oral ciprofloxacin or amoxicillin-clavulanate for treatment of complicated urinary tract infections in adults. Study Number: IT001-302 Study Phase: Phase 3 Product Name: Sulopenem (CP-70,429), Sulopenem-etzadroxil (PF-03709270)/Probenecid Indication: Complicated urinary tract infection Study Statistician: Michael Zelasky Study Clinician: Steven I. Aronin, M.D. Sponsor: Iterum Therapeutics International Limited 20 Research Parkway, Suite A Old Saybrook, CT 06475 Final SAP Date: September 25, 2019 Revised SAP Date: February 11, 2020 Protocol Version: January 16, 2020 Confidentiality Statement This document is strictly confidential. It was developed by Iterum Therapeutics US Limited should not be disclosed to a third party, with the exception of regulatory agencies and study audit personnel. Reproduction, modification or adaptation, in part or in total, is strictly forbidden without prior written approval by Iterum Therapeutics US Limited Digitally signed by Anita F Das DN: cn=Anita F Das, o, ou, [email protected]. Anita F Das com, c=US Date: 2020.02.12 12:57:12 -08'00' Sulopenem IV; Sulopenem etzadroxil Iterum Therapeutics Statistical Analysis Plan: IT001-302 11 February 2020 TABLE OF CONTENTS TABLE OF CONTENTS........................................................................................................... -
Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre, -
Vaginal Discharge, Itching Vaginal Bleeding, Amenorrhea
Common Problem of the Gynecological System Vaginal Discharge, itching vaginal bleeding, amenorrhea 本講義表格資料取自Dains, J.E., Baumann, L.C., & Scheibel, P. (2007). Advanced assessment and clinical diagnosis in primary care. (3rd ed). St. Louis: Mosby. 1 圖片取自Seidel HM, Ball JW, Dains JE, Benedict GW. (1999). Mosby’s guide to physical examination. St. Louis, MO: Mosby. VildihVaginal discharge and itching 2 Vaginitis • Inflammation of vaggggina, cause vaginal discharge • In child bearing women, 95% due to • Trichomonas vaginalis (陰道滴蟲), • Candida, • bacteria vaginosis (BV): • epithelium is not inflamed • Risk for premature rupture of mambrane and early delivery • Postmenopausal women: atrophic vaginitis • In young girl: vulvovaginitis • due to hypoestrogenic state and poor perineal hygiene 3 Characteristic of discharge • Copious, greenish, offensive-smelling: • Trichomonas vaginalis • Mucopurulent or purulent • Gonorrhea and Chlamyy(dia (披衣菌) • Moderate amount, white, curd-like discharge • Candida vulvovaginitis • CittithithiConsistent with itching • Birth control pills, steroid, antibiotic, chemotherapy • Thin white,,g green, ,g grey or brownish •BV • Also with fishly odor • Need microscopic exam to confirm the diagnosis 4 Lesion • Vesicle • Herpes • Papular on labia, perineum, and anal area • CdlCondyloma tlt(ta lata(扁平濕疣)dllt), condyllomata acuminata(尖型濕疣), • Malluscum contagiosum (傳染性軟疣) • Painless ulcer • Syphilis 5 Pelvic infection disease • Cervical motion tender (CMT) • Pain on palpation of uterus and adnexa • Purulent discharge • Need -
Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate. -
Vaginitis No Disclosures Related to This Topic
Vaginitis No disclosures related to this topic Is the wet prep out of the building? Images are cited with permissions Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health Center Michigan Medicine Ann Arbor, Michigan Women with vaginal discharge Is vaginal discharge ever “normal ”? Normal 30% Bacterial vaginosis 23-50% Few primary studies and most of low quality. Candida vaginitis 20-25% Quantity and quality of vaginal discharge varies considerably across women and during the Mixed 20% menstrual cycle. Desquamative inflammatory 8% Symptom of vaginal discharge is non-specific. Vaginitis Vaginal discharge is often thought to be vaginitis. Trichomoniasis 5-15% Vaginal symptoms are very common Patient with chronic vaginal discharge Presence or absence of a microbe corresponds poorly with the presence or absence of 17 year old GO complains of lots of heavy white symptoms. vaginal discharge which is bothersome. No agreement about timing, color or Regular periods, denies any sexual activity. characteristics of discharge among women with Numerous evaluations for STI’s, all negative. vaginal discharge Treated for vaginal candida, BV and trich Most women think vagina should be “dry ”. although there was no evidence for any Vaginal wetness may be normal . infection and did not resolve discharge. Schaaf et al. Arch Intern Med 1999;150. Physiologic vaginal discharge 17 year old Chronic vaginal Patients and providers may consider that a thick discharge white discharge is most frequently caused by candidiasis. Always wears a pad May lead to repeated use of unnecessary antifungal therapy and prompt concerns of Diagnosis? recurrent infection if not resolved. -
How to Evaluate Vaginal Bleeding and Discharge
How to Evaluate Vaginal Bleeding and Discharge Is the bleeding normal or abnormal? When does vaginal discharge reflect something as innocuous as irritation caused by a new soap? And when does it signal something more serious? The authors’ discussion of eight actual patient presentations will help you through the next differential diagnosis for a woman with vulvovaginal complaints. By Vincent Ball, MD, MAJ, USA, Diane Devita, MD, FACEP, LTC, USA, and Warren Johnson, MD, CPT, USA bnormal vaginal bleeding or discharge is typically due to either inadequate levels of estrogen one of the most common reasons women or a persistent corpus luteum. Structural causes of come to the emergency department.1,2 bleeding include leiomyomas, endometrial polyps, or Because the possible underlying causes malignancy. Infectious etiologies include pelvic in- Aare diverse, the patient’s age, key historical factors, flammatory disease (PID). Additionally, a variety of and a directed physical examination are instrumental bleeding dyscrasias involving platelet or clotting fac- in deciding on diagnosis and treatment. This article tors can complicate the normal menstrual period. Iat- will review some common case presentations of rogenic causes of vaginal bleeding include hormone nonpregnant female patients with abnormal vaginal replacement therapy, steroid hormone contraception, bleeding, inflammation, or discharge. and contraceptive intrauterine devices.3-5 Anovulatory bleeding is common in perimenar- ABNORMAL VAGINAL BLEEDING chal girls as a result of an immature hypothalamic- To ensure appropriate patient management, “Is she pituitary axis and in perimenopausal women due to pregnant?” should be the first question addressed, declining levels of estrogen. During reproductive since some vulvovaginal signs and symptoms will years, dysfunctional uterine differ in significance and urgency depending on the bleeding (DUB) is the most >>FAST TRACK<< answer. -
Metronidazole/Nifuratel 841
Metronidazole/Nifuratel 841 African trypanosomiasis. Although there is no established al- Monensin (BAN, USAN, rINN) Nicarbazin (BAN) ternative treatment for Trypanosoma brucei rhodesiense infec- Lilly-67314; Monensina; Monensinum. 4-{2-[2-Ethyl-3′-methyl- Nicarbazina. An equimolecular complex of 1,3-bis(4-nitro- tions that are resistant to melarsoprol (see p.827), metronidazole 5′-(tetrahydro-6-hydroxy-6-hydroxymethyl-3,5-dimethylpyran- phenyl)urea (C13H10N4O5) and 4,6-dimethylpyrimidin-2-ol 1 and suramin were effective in 1 patient. 2-yl)perhydro-2,2′-bifuran-5-yl]-9-hydroxy-2,8-dimethyl-1,6-di- (C6H8N2O). 1. Foulkes JR. Metronidazole and suramin combination in the treat- oxaspiro[4.5]dec-7-yl}3-methoxy-2-methylpentanoic acid. Никарбазин ment of arsenical refractory rhodesian sleeping sickness—a case Монензин C H N O = 426.4. study. Trans R Soc Trop Med Hyg 1996; 90: 422. 19 18 6 6 C36H62O11 = 670.9. CAS — 330-95-0. Preparations CAS — 17090-79-8. ATC Vet — QP51AE03. ATC Vet — QP51AH03. BP 2008: Metronidazole Gel; Metronidazole Intravenous Infusion; Metron- idazole Oral Suspension; Metronidazole Suppositories; Metronidazole Tab- lets; NHO CH3 USP 31: Metronidazole Gel; Metronidazole Injection; Metronidazole Tab- CH3 CH H lets. 3 N Proprietary Preparations (details are given in Part 3) O O- O- Arg.: Bexon; Colpofilin; Dazotron; Epaq†; Etronil; Flagyl; Format; Ginkan; H H CH3 OO + CH3 + Gynotran; Metral; Metrocev; Metrolocal; Nalox; Noritate†; Padet; Repligen; HO H3C N N Rozex; Taremis; Tolbin; Tricofin; Trimstat†; Austral.: Flagyl; Metrogyl; -
Training Manual
Training of Trainers Program on Analysis of Veterinary Drug Residues including Antibiotics TRAINING MANUAL Name: __________________________________ Email: __________________________________ Organized by: FSSAI & GFSP in association with PBTI at Punjab Biotechnology Incubator, Mohali, Punjab February, 2018 MANUAL FOR VETERINARY DRUG RESIDUE ANALYSIS INCLUDING ANTIBIOTICS Food Safety and Standards Authority of India Ministry of Health and Family Welfare, Government of India Manual for veterinary drug residue analysis including antibiotics, 2018. © 2018 by Food Safety and Standards Authority of India, New Delhi. All rights reserved. No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical or photocopying, recording or otherwise without the prior written permission of the publisher or authors. ABOUT THE MANUAL The current manual borrows its majority of content and structure from the Training of Trainers (ToT) manual prepared by IFSTL partners USFDA, USDA and JIFSAN and with their consent. This manual is complementary to the workshop laboratory manual and lecture notes. The manual is meant to provide future trainers with an opportunity to make notes on various aspects of logistics associated with giving the training to a group. COPYRIGHT NOTICE The contents of the manual are protected by the terms of the Food Safety and Standard Authority of India (FSSAI), Ministry of Health and Family Welfare, Govt. of India. Permission to use whole or parts of texts contained in this manual in printed or electronic form must be obtained and is usually subject to royalty agreements. Proposals for non-commercial reproductions and translations are welcomed and considered on a case-by-case basis. -
Use of Nifuratel to Treat Infections Caused by Atopobium Species
(19) & (11) EP 2 243 482 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.10.2010 Bulletin 2010/43 A61K 31/422 (2006.01) A61P 15/02 (2006.01) A61P 31/04 (2006.01) A61P 13/02 (2006.01) (2006.01) (21) Application number: 09158221.3 A61P 15/00 (22) Date of filing: 20.04.2009 (84) Designated Contracting States: (72) Inventor: Mailland, Federico AT BE BG CH CY CZ DE DK EE ES FI FR GB GR CH-6900 Lugano (CH) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: Pistolesi, Roberto et al Designated Extension States: Dragotti & Associati Srl AL BA RS Via Marina 6 20121 Milano (IT) (71) Applicant: Polichem SA 1526 Luxembourg (LU) (54) Use of nifuratel to treat infections caused by atopobium species (57) The present invention is directed to the use of genitalia in both sexes, as well as bacterial vaginosis, or nifuratel, or a physiologically acceptable salt thereof, to mixed vaginal infections in women, when one or more treat infections caused by Atopobium species. The in- species of the genus Atopobium are among the causative vention is further directed to the use of nifuratel to treat pathogens of those infections. bacteriuria, urinary tract infections, infections of external EP 2 243 482 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 243 482 A1 Description [0001] The present invention relates to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species. -
Clinicomicrobiological Spectrum of Abnormal Discharge from Vagina in Women in Costal Andhra Pradesh
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Singamsetty J et al. Int J Reprod Contracept Obstet Gynecol. 2021 Jan;10(1):150-153 www.ijrcog.org pISSN 2320-1770 | eISSN 2320-1789 DOI: https://dx.doi.org/10.18203/2320-1770.ijrcog20205760 Original Research Article Clinicomicrobiological spectrum of abnormal discharge from vagina in women in costal Andhra Pradesh Jyothi Singamsetty, G. Sravani* Department of Obstetrics and Gynaecology, Konaseema Institute of Medical Science Amalapuram, Andhra Pradesh India Received: 30 November 2020 Accepted: 17 December 2020 *Correspondence: Dr. G. Sravani, E-mail: [email protected] Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Background: When there is change in colour, consistency, order and volume of discharge then it is called abnormal vaginal discharge and associated with vulvar pruritus, dyspareunia, dysuria and lower abdominal pain. There is variability in organism isolated and treatment used. Methods: Sexually active women in reproductive age group with complain of abnormal vaginal discharge were included in this study based in following inclusion and exclusion criteria. A detailed history of patient was taken regarding nature of discharge, colour, smell along with dysuria, dyspareunia, itching of vulva and lower abdominal pain. Results: Out of 160 patients 88 patients have bacterial vaginosis. Trichomonas vaginitis was present in 7.5% patients. Candidiasis was present in 6.25% patients. Some patients were having more than one infection like Bacterial vaginosis and Trichomonas vaginitis was coexisting in 13.75%, Bacterial vaginosis + Candidiasis were present in 8.75% patients. -
OBGYN-Study-Guide-1.Pdf
OBSTETRICS PREGNANCY Physiology of Pregnancy: • CO input increases 30-50% (max 20-24 weeks) (mostly due to increase in stroke volume) • SVR anD arterial bp Decreases (likely due to increase in progesterone) o decrease in systolic blood pressure of 5 to 10 mm Hg and in diastolic blood pressure of 10 to 15 mm Hg that nadirs at week 24. • Increase tiDal volume 30-40% and total lung capacity decrease by 5% due to diaphragm • IncreaseD reD blooD cell mass • GI: nausea – due to elevations in estrogen, progesterone, hCG (resolve by 14-16 weeks) • Stomach – prolonged gastric emptying times and decreased GE sphincter tone à reflux • Kidneys increase in size anD ureters dilate during pregnancy à increaseD pyelonephritis • GFR increases by 50% in early pregnancy anD is maintaineD, RAAS increases = increase alDosterone, but no increaseD soDium bc GFR is also increaseD • RBC volume increases by 20-30%, plasma volume increases by 50% à decreased crit (dilutional anemia) • Labor can cause WBC to rise over 20 million • Pregnancy = hypercoagulable state (increase in fibrinogen anD factors VII-X); clotting and bleeding times do not change • Pregnancy = hyperestrogenic state • hCG double 48 hours during early pregnancy and reach peak at 10-12 weeks, decline to reach stead stage after week 15 • placenta produces hCG which maintains corpus luteum in early pregnancy • corpus luteum produces progesterone which maintains enDometrium • increaseD prolactin during pregnancy • elevation in T3 and T4, slight Decrease in TSH early on, but overall euthyroiD state • linea nigra, perineum, anD face skin (melasma) changes • increase carpal tunnel (median nerve compression) • increased caloric need 300cal/day during pregnancy and 500 during breastfeeding • shoulD gain 20-30 lb • increaseD caloric requirements: protein, iron, folate, calcium, other vitamins anD minerals Testing: In a patient with irregular menstrual cycles or unknown date of last menstruation, the last Date of intercourse shoulD be useD as the marker for repeating a urine pregnancy test.